IL-5 Protein, Mouse

Catalog Number: UA040090 Reactivity: Mouse Conjugation: Unconjugated Brand: UA BIOSCIENCE

Price:

$209.00 SGD

Size: 10μg 50μg 100μg 500μg 1mg

Quantity:

For shipping services or bulk orders, you may request a quotation.

Secure checkout with

View full details

Product Details

Product Specification

Species	Mouse
Synonyms	IL-5, rRtIL-5, EDF, BCDFII, TRF
Accession	P04401
Amino Acid Sequence	Met21-Gly133
Expression System	E.coli
Molecular Weight	13kDa
Purity	>95% by SDS-PAGE
Endotoxin	<1EU/μg
Conjugation	Unconjugated
Tag	No Tag
Physical Appearance	Lyophilized Powder
Storage Buffer	20mM Tris, 150mM NaCl, pH9.0
Reconstitution	Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation.
Stability & Storage	· 12 months from date of receipt, lyophilized powder stored at -20 to -80℃. · 3 months, -20 to -80℃ under sterile conditions after reconstitution. · 1 week, 2 to 8℃ under sterile conditions after reconstitution. · Please avoid repeated freeze-thaw cycles.
Reference	1、Milburn M V. et al. (1993) A novel dimer configuration revealed by the crystal structure at 2.4 A resolution of human interleukin-5. Nature. 363(6425): 172-176. 2、Woodcock J M. et al. (1994) Three residues in the common beta chain of the human GM-CSF, IL-3 and IL-5 receptors are essential for GM-CSF and IL-5 but not IL-3 high affinity binding and interact with Glu21 of GM-CSF. EMBO J. 13 (21): 5176-85.

Background

Interleukin 5 (IL-5) is predominantly produced by Th2 cells to regulate differentiation and proliferation of eosinophils. As the major cytokine in eosinophil development, IL-5 induces eosinophil migration, activation, and survival. The primary source of IL-5 is TH2 lymphocytes, but mast cells are also a source in the airways. IL-5 is increased in bronchial biopsies and BAL fluid and serum from symptomatic asthmatic patients, knockout of IL-5 in mice eliminates AHR and eosinophilia, and overexpression or treatment with rIL-5 results in asthma-like lung histopathology. Blockade of IL-5 in humans with mepolizumab, an anti-IL-5 antibody, decreases eosinophils in the sputum and general circulation, and in asthma patients exhibiting hypereosinophilia and resistance to steroid therapy mepolizumab reduces exacerbations.